Seminars in Oncology
Volume 33 , Pages 8-12 , April 2006

Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial

  • Paul E. Goss

      Affiliations

    • Dr Goss has served as a member of an advisory board for Novartis, Pfizer and Astra-Zeneca. He has received honoraria from Novartis, Pfizer and Astra-Zeneca.
    • Corresponding Author InformationAddress correspondence and reprint requests to Paul E. Goss, MD, PhD, Massachusetts General Hospital Cancer Center, 55 Fruit St, Cox Bldg, Room 640, Boston, MA 02114.

References 

  1. Dunn BK , Wickerham DL , Ford LG . Prevention of hormone-related cancers (breast cancer) . J Clin Oncol . 2005;23:357–367
  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) . Tamoxifen for early breast cancer (An overview of the randomized trials) . Lancet . 1998;351:1451–1467
  3. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer (Status report 2002) . J Clin Oncol . 2002;20:3317–3327
  4. Fisher B , Dignam J , Bryant J , et al.   Five versus more than five years of tamoxifen for lymph node-negative breast cancer (Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial) . J Natl Cancer Inst . 2001;93:684–690
  5. Hortobagyi GN , Kau S-W , Buzdar AU , et al.   What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? . Proc Am Soc Clin Oncol . 2004;22:23; (abstr)
  6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival (An overview of the randomised trials) . Lancet . 2005;365:1687–1717
  7. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer (Status report 2004) . J Clin Oncol . 2005;23:1–11
  8. Geisler J , Haynes B , Anker G , et al.   Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study . J Clin Oncol . 2002;20:751–757
  9. Lu Q , Yue W , Wang J , et al.   The effects of aromatase inhibitors and antiestrogens in the nude mouse model . Breast Cancer Res Treat . 1998;50:63–71
  10. Brodie A , Lu Q , Liu Y , Long B . Aromatase inhibitors and their antitumor effects in model systems . Endocr Relat Cancer . 1999;6:205–210
  11. Eiermann W , Paepke S , Appfelstaedt J , et al.   Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study . Ann Oncol . 2001;12:1527–1532
  12. Mouridsen HT , Robert NJ . The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women . Eur J Cancer . 2005;41:1678–1689
  13. Goss PE . Changing clinical practice (Extending the benefits of adjuvant endocrine therapy in breast cancer) . Semin Oncol . 2004;31(suppl):15–22
  14. Wasan KM , Goss PE , Pritchard PH , et al.   The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) . Ann Oncol . 2005;16:707–715
  15. Perez EA , Josse RG , Pritchard KI , et al.   Effect of letrozole versus placebo on bone mineral density in women completing ≥5 years (yrs) of adjuvant tamoxifen (NCIC CTG MA.17b) . Breast Cancer Res Treat . 2004;88(suppl 1):S36; (abstr 404)
  16. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N Engl J Med . 2003;349:1793–1802
  17. Goss PE , Ingle JN , Martino S , et al.   Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer (Updated findings from NCIC CTG MA.17) . J Natl Cancer Inst . 2005;97:1262–1271
  18. Goss PE , Ingle JN , Martino S , et al.   Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer . Proc Am Soc Clin Oncol . 2004;22:88; (abstr)
  19. Kaufman M , Rody A . Long-term risk of breast cancer recurrence (the need for extended adjuvant therapy) . J Cancer Res Clin Oncol . 2005;131:487–494
  20. Lamerato L , Havstad S , Gandhi S , Jones D , Chlebowski R . Breast cancer recurrence and related mortality in US pts with early breast cancer . J Clin Oncol . 2005;23(suppl):62s; (abstr 738)
  21. Whelan TJ , Goss PE , Ingle JN , et al.   Assessment of quality of life in MA.17 (A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women) . J Clin Oncol . 2005;23:6931–6940
  22. Brufsky A , Harker G , Beck T , et al.   Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let) (12 Months BMD results of the Z-FAST trial) . Proc Am Soc Clin Oncol . 2005;23:12S; (abstr 533)

PII: S0093-7754(06)00173-4

doi: 10.1053/j.seminoncol.2006.03.025

Seminars in Oncology
Volume 33 , Pages 8-12 , April 2006

Article Tools

* Image Usage & Resolution